Is Theravance Biopharma, Inc. (TBPH) halal? Not Halal. Based on AAOIFI screening, Theravance Biopharma, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
TBPH: Is Theravance Biopharma, Inc. Halal?
Not HalalTheravance Biopharma, Inc.
$15.58
-2.26%
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Sector: Healthcare 路 Industry: Biotechnology
Shariah Compliance Status
Non-Compliant
Fails Shariah screening
Business Activity Screen
PassedChecks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)
Financial Ratio Screen
FailedFinancial ratios must be below AAOIFI thresholds
Compliance History
Not Halal, unchanged since May 2026.
No status changes recorded since we began tracking.
Tracked since May 2026. Updates automatically on each re-screen.
Financial Overview
Market Cap
803.2M
Price
$15.58
Sector
Healthcare
Industry
Biotechnology
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Track TBPH and 10,000+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Frequently Asked Questions
Is Theravance Biopharma, Inc. (TBPH) halal to invest in?
Why did Theravance Biopharma, Inc. get a F compliance rating?
What could change Theravance Biopharma, Inc.'s Shariah verdict?
How often is Theravance Biopharma, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 路 For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.